Abkyu

Startup

Abkyu is a Boston-based antibody discovery company specializing in in vivo strategies for VHH (single-domain antibody) discovery. Leveraging proprietary genetic immunization techniques and next-generation sequencing (NGS) of evolving immune repertoires, we offer a powerful platform to identify VHHs against challenging targets—including complex cell surface proteins and GPCRs.
Our approach includes rapid immunization timelines (as short as 60 days), pre-selection of genetically diverse animals, and deep immune profiling to deliver VHH panels with broad epitope and affinity diversity. Combined with favorable business terms, this enables a de-risked path to discovering high-value lead candidates.
Abkyu’s services range from immunization and delivery of immune material to support our partners’ internal discovery platforms, to full-service discovery and humanization of lead therapeutic assets. Our fee-for-service model is designed to empower the drug discovery community—with both access to cutting-edge tools for lead panel diversity and the flexibility for downstream development and investment.
At Abkyu, we are committed to accelerating the development of next-generation therapeutics by enabling our partners to efficiently and confidently generate VHH molecules against some of the industry’s most difficult targets.